Huaren Pharmaceutical Co., Ltd. (SHE:300110)
China · Delayed Price · Currency is CNY 3.320
+0.060 (1.84%)
Feb 4, 2026, 3:04 PM CST
Huaren Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,240 | 1,338 | 1,540 | 1,576 | 1,561 | 1,313 |
Other Revenue | 15.41 | 15.41 | 96.11 | 43.04 | - | 3.18 |
| 1,256 | 1,353 | 1,636 | 1,619 | 1,561 | 1,317 | |
Revenue Growth (YoY) | -15.94% | -17.30% | 1.03% | 3.76% | 18.55% | -9.94% |
Cost of Revenue | 842.45 | 885.61 | 940.42 | 923.59 | 800.71 | 762.06 |
Gross Profit | 413.36 | 467.55 | 695.83 | 695.9 | 760.15 | 554.53 |
Selling, General & Admin | 241.89 | 242.68 | 310.45 | 330.23 | 399.91 | 319.24 |
Research & Development | 71.08 | 72.29 | 68.68 | 55.3 | 63.68 | 55.22 |
Other Operating Expenses | 13.38 | 12.68 | 20.06 | 27.13 | 27.73 | 24.09 |
Operating Expenses | 349.27 | 337.5 | 350.99 | 451.32 | 533.51 | 437.47 |
Operating Income | 64.09 | 130.05 | 344.84 | 244.58 | 226.64 | 117.06 |
Interest Expense | -45.22 | -54.32 | -61.51 | -64.16 | -63.14 | -10.96 |
Interest & Investment Income | 2.62 | 0.93 | 3 | 4.77 | 1.8 | 4.75 |
Currency Exchange Gain (Loss) | 0.14 | 0.14 | 0.24 | 0.15 | -0.07 | 0.01 |
Other Non Operating Income (Expenses) | -1,341 | -1,345 | -64.89 | -16.15 | -22.13 | -6.91 |
EBT Excluding Unusual Items | -1,319 | -1,268 | 221.68 | 169.18 | 143.1 | 103.95 |
Impairment of Goodwill | -87.43 | -87.43 | -6.25 | -0.35 | - | - |
Gain (Loss) on Sale of Investments | -1.17 | -1.17 | - | -1.39 | -0.87 | -0.71 |
Gain (Loss) on Sale of Assets | 0.01 | 0.02 | 4.35 | 13.86 | -0.17 | - |
Asset Writedown | 0.2 | -0.14 | -0.78 | -6.34 | - | -0.04 |
Other Unusual Items | 0.71 | 0.71 | 11.51 | 30.89 | 8.2 | 8.44 |
Pretax Income | -1,407 | -1,356 | 230.51 | 205.86 | 150.26 | 111.64 |
Income Tax Expense | -0.98 | 7.08 | 37.09 | 24.56 | 16.21 | 14.75 |
Earnings From Continuing Operations | -1,406 | -1,363 | 193.42 | 181.3 | 134.05 | 96.89 |
Minority Interest in Earnings | -3.52 | -5.65 | -5.36 | -0.52 | -3.65 | -2.27 |
Net Income | -1,409 | -1,368 | 188.06 | 180.78 | 130.4 | 94.62 |
Net Income to Common | -1,409 | -1,368 | 188.06 | 180.78 | 130.4 | 94.62 |
Net Income Growth | - | - | 4.03% | 38.63% | 37.81% | 124.94% |
Shares Outstanding (Basic) | 1,181 | 1,182 | 1,182 | 1,182 | 1,185 | 1,183 |
Shares Outstanding (Diluted) | 1,181 | 1,182 | 1,182 | 1,182 | 1,185 | 1,183 |
Shares Change (YoY) | -0.08% | 0.01% | 0.04% | -0.33% | 0.23% | 1.22% |
EPS (Basic) | -1.19 | -1.16 | 0.16 | 0.15 | 0.11 | 0.08 |
EPS (Diluted) | -1.19 | -1.16 | 0.16 | 0.15 | 0.11 | 0.08 |
EPS Growth | - | - | 3.99% | 39.09% | 37.50% | 122.22% |
Free Cash Flow | 249.48 | 297.67 | 259.74 | 175.65 | -606.38 | -68.71 |
Free Cash Flow Per Share | 0.21 | 0.25 | 0.22 | 0.15 | -0.51 | -0.06 |
Dividend Per Share | - | - | 0.021 | 0.021 | 0.018 | 0.015 |
Dividend Growth | - | - | - | 16.67% | 20.00% | 50.00% |
Gross Margin | 32.92% | 34.55% | 42.53% | 42.97% | 48.70% | 42.12% |
Operating Margin | 5.10% | 9.61% | 21.07% | 15.10% | 14.52% | 8.89% |
Profit Margin | -112.23% | -101.13% | 11.49% | 11.16% | 8.36% | 7.19% |
Free Cash Flow Margin | 19.87% | 22.00% | 15.87% | 10.85% | -38.85% | -5.22% |
EBITDA | 173.06 | 246.27 | 470.74 | 393.17 | 361.03 | 230.51 |
EBITDA Margin | 13.78% | 18.20% | 28.77% | 24.28% | 23.13% | 17.51% |
D&A For EBITDA | 108.97 | 116.22 | 125.9 | 148.59 | 134.39 | 113.45 |
EBIT | 64.09 | 130.05 | 344.84 | 244.58 | 226.64 | 117.06 |
EBIT Margin | 5.10% | 9.61% | 21.07% | 15.10% | 14.52% | 8.89% |
Effective Tax Rate | - | - | 16.09% | 11.93% | 10.79% | 13.21% |
Revenue as Reported | 1,256 | 1,353 | 1,636 | 1,619 | - | 1,317 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.